Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

CompletedOBSERVATIONAL
Enrollment

496

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Breast NeoplasmsBreast Diseases
Interventions
DEVICE

OSNA Breast Cancer System

"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."

Trial Locations (11)

10003

Beth Israel Medical Center, New York

18104

Breast Care Specialist, PC, Allentown

27157

Wake Forest University Health Sciences, Winston-Salem

27401

Central Carolina Surgery, PA, Greensboro

30062

WellStar Health Systems, Marietta

37203

Nashville Breast Center, PC, Nashville

43081

Breast Care Specialist, Inc., Westerville

63110

Washington University Medical School, St Louis

75230

Dallas Surgical Group, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

90404

John Wayne Cancer Institute, Santa Monica

All Listed Sponsors
lead

Sysmex America, Inc.

INDUSTRY

NCT01136369 - Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer | Biotech Hunter | Biotech Hunter